SCHEMBL11245866

SCHEMBL11245866

O=C(O)CC(CC(=O)O)(OC(=O)CCC(=O)OC(CC(=O)O)(CC(=O)O)C(=O)O)C(=O)O.[Fe].[Fe].[NaH].[NaH]

nearest known ligand 0.36

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.36
TSHR P16473 2/20 0.34
CYP2D6 P10635 1/20 0.34
CYP2C19 P33261 1/20 0.34
HIF1A Q16665 1/20 0.34
HMGCR P04035 1/20 0.31
CHRM1 P11229 1/20 0.31
TBXA2R P21731 1/20 0.31
ADRA1A P35348 1/20 0.31
ACLY P53396 2/20 0.30
KDM6B O15054 1/20 0.30
KDM5C P41229 1/20 0.30
EGLN1 Q9GZT9 1/20 0.30
PHF8 Q9UPP1 1/20 0.30
KDM2A Q9Y2K7 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27076088 0.98 ALDH1A1 (0.37) ALDH1A1TSHRCYP2D6CYP2C19HIF1A
SCHEMBL28452924 0.98 ALDH1A1 (0.37) ALDH1A1TSHRCYP2D6CYP2C19HIF1A
SCHEMBL9241914 0.96 EGLN1 (0.36) ALDH1A1TSHRCYP2D6CYP2C19HIF1A
SCHEMBL1989298 0.96 ALDH1A1 (0.39) ALDH1A1TSHRCYP2D6CYP2C19HIF1A
SCHEMBL119741 0.91 EGLN1 (0.39) ALDH1A1TSHRCYP2D6CYP2C19HIF1A
Succinic Acid SCHEMBL8002651 0.91 EGLN1 (0.39) ALDH1A1TSHRCYP2D6CYP2C19HIF1A
SCHEMBL10410369 0.89 TSHR (0.41) ALDH1A1TSHRCYP2D6CYP2C19HIF1A
Succinic Acid SCHEMBL1871339 0.88 EGLN1 (0.36) ALDH1A1TSHRCYP2D6CYP2C19HIF1A
SCHEMBL2761469 0.85 TSHR (0.48) ALDH1A1TSHRCYP2D6CYP2C19HIF1A
SCHEMBL5158691 0.85 LMNA (0.46) ALDH1A1TSHRCYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240173283-A1 PROPHYLACTIC AGENT OR THERAPEUTIC AGENT FOR SIDE EFFECTS OF ANTHRACYCLINE ANTICANCER AGENT SBI PHARMACEUTICALS CO., LTD. (JP) 2024-05-30 US claimed
EP-4316480-A1 PROPHYLACTIC AGENT OR THERAPEUTIC AGENT FOR SIDE EFFECTS OF ANTHRACYCLINE ANTICANCER AGENT Kyushu University, National University Corporation (JP) 2024-02-07 EP claimed
US-4362710-A Feeds for baby pigs, process for preparing the same and method of breeding baby pigs NISSAN GOSEI KOGYO CO., LTD. (JP) 1982-12-07 US claimed
US-20240173283-A1 PROPHYLACTIC AGENT OR THERAPEUTIC AGENT FOR SIDE EFFECTS OF ANTHRACYCLINE ANTICANCER AGENT SBI PHARMACEUTICALS CO., LTD. (JP) 2024-05-30 US disclosed
EP-4316480-A1 PROPHYLACTIC AGENT OR THERAPEUTIC AGENT FOR SIDE EFFECTS OF ANTHRACYCLINE ANTICANCER AGENT Kyushu University, National University Corporation (JP) 2024-02-07 EP disclosed
US-11633505-B2 Nuclear magnetic resonance diagnostic agent, and method for detecting or diagnosing state of cell, tissue or organ in subject using same NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSITY (JP) 2023-04-25 US disclosed
WO-2022215655-A1 LIVESTOCK FEED 住友化学株式会社 2022-10-13 WO disclosed
WO-2022202477-A1 PROPHYLACTIC AGENT OR THERAPEUTIC AGENT FOR SIDE EFFECTS OF ANTHRACYCLINE ANTICANCER AGENT 国立大学法人九州大学 2022-09-29 WO disclosed
WO-2022176904-A1 LIVESTOCK FEED 住友化学株式会社 2022-08-25 WO disclosed
WO-2022176902-A1 LIVESTOCK FEED 住友化学株式会社 2022-08-25 WO disclosed
WO-2022176903-A1 LIVESTOCK FEED 住友化学株式会社 2022-08-25 WO disclosed
WO-2022131287-A1 LIVESTOCK FEED 住友化学株式会社 2022-06-23 WO disclosed
WO-2022131288-A1 ABSCISIC ACID-MIXED PIG FEED 住友化学株式会社 2022-06-23 WO disclosed
WO-2021215517-A1 THERAPEUTIC AND/OR PREVENTIVE AGENT FOR CORONAVIRUS DISEASE 2019 (COVID-19) ネオファーマジャパン株式会社 (JP) 2021-10-28 WO disclosed
WO-2021132626-A1 THERAPEUTIC AND/OR PREVENTIVE AGENT FOR CLASSICAL SWINE FEVER 国立大学法人北海道大学 2021-07-01 WO disclosed
WO-2021054473-A1 AGENT FOR AMELIORATING AND/OR PREVENTING SICKLE CELL DISEASE 国立大学法人 東京大学 2021-03-25 WO disclosed
CN-104487066-B Prophylactic and/or therapeutic agent for radiation damage 国立大学法人东京大学 2020-06-09 CN disclosed
EP-2932983-B1 NUCLEAR MAGNETIC RESONANCE DIAGNOSTIC AGENT, AND USE THEREOF IN A METHOD FOR DETECTING OR DIAGNOSING STATE OF CELL, TISSUE OR ORGAN IN SUBJECT UNIV KUMAMOTO NAT UNIV CORP (JP) 2018-09-12 EP disclosed
US-20150320888-A1 NUCLEAR MAGNETIC RESONANCE DIAGNOSTIC AGENT, AND METHOD FOR DETECTING OR DIAGNOSING STATE OF CELL, TISSUE OR ORGAN IN SUBJECT USING SAME UNIV KUMAMOTO NAT UNIV CORP (JP) 2015-11-12 US disclosed
EP-2932983-A1 NUCLEAR MAGNETIC RESONANCE DIAGNOSTIC AGENT, AND METHOD FOR DETECTING OR DIAGNOSING STATE OF CELL, TISSUE OR ORGAN IN SUBJECT USING SAME National University Corporation Kumamoto University (JP) 2015-10-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150320888-A1 NUCLEAR MAGNETIC RESONANCE DIAGNOSTIC AGENT, AND METHOD FOR DETECTING OR DIAGNOSING STATE OF CELL, TISSUE OR ORGAN IN SUBJECT USING SAME GOT1, GOT2, AADAT ALDH1A1 1304/4885TSHR 3477/4885CYP2D6 1689/4885
US-11633505-B2 Nuclear magnetic resonance diagnostic agent, and method for detecting or diagnosing state of cell, tissue or organ in subject using same GOT1, GOT2, AADAT ALDH1A1 1304/4885TSHR 3477/4885CYP2D6 1689/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.